The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

The study, led by Vall d'Hebron, is the first in Spain to analyse the relationship between pregnancy complications and the risk of long-term cardiovascular diseases.

The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.

The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.

In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.

Vall d'Hebron researchers have created a score based on multiple clinical variables and cardiac images, specific to women, to identify patients at risk of severe complications such as a heart attack or sudden death.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The study on the effects of diesel particles on the heart has been recognized as the best research work from Spain at the association’s Scientific Sessions.

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

The funds will strengthen research lines focused on nervous system tumors.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

The Vall d’Hebron Institute of Research’s Paediatric Cancer and Hematological Diseases Research Group Achieves Promising Results for Acute Graft-Versus-Host Disease.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

The study, which provides guidelines for the clinical management of these patients, reveals that only children with a recent stem cell transplant or with other additional diseases have a higher risk of complications from COVID-19.

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.